Clinical Research Directory

Inclusion Criteria 1. Adults \>/= 18 years old 2. Laboratory confirmed influenza A and/or B (rapid test or PCR) 3. Able to be enrolled, randomized, and dosed with study drug within 8 hours of the decision to admit patient to hospital for treatment of influenza 4. Oseltamivir treatment ordered by clinical team AND patient is able to be enrolled: * Prior to the initial dose of oseltamivir OR * Within 60 minutes after the initial dose of oseltamivir 5. Subject or Legally Authorized Representative able to and willing to provide written informed consent 6. Able to commit to 30 days of follow up 7. Weight \> 40 kg 8. SARS-CoV-2 PCR swab sent within 1 week of enrollment Exclusion Criteria 1. ESRD not undergoing hemodialysis (HD) or peritoneal dialysis (CAPD) 2. Severe hepatic insufficiency, cirrhosis, acute or chronic liver failure 3. Nausea/vomiting, aspiration risk, or other conditions precluding the ability to use oral medications (if patient is NPO including meds, otherwise unable to swallow oral medications) 4. Influenza medication use within the prior week, other than the initial oseltamivir given during this hospitalization for this episode of influenza 5. Oseltamivir or baloxavir allergy or intolerance 6. Pregnancy (need negative pregnancy test (urine or blood) in reproductive age women) 7. Absence of dependable contraception in reproductive age women 8. Inability to obtain informed consent 9. Refusal of oseltamivir therapy by patient as baseline treatment